CINECA IRIS Institutional Research Information System

PELLEGRINI, CAROLINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.576
AS - Asia 2.932
EU - Europa 2.741
SA - Sud America 489
AF - Africa 170
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 1
Totale 11.921
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.422
IT - Italia 1.323
SG - Singapore 947
CN - Cina 864
HK - Hong Kong 536
BR - Brasile 415
SE - Svezia 278
DE - Germania 244
VN - Vietnam 172
BG - Bulgaria 162
GB - Regno Unito 135
RU - Federazione Russa 128
FI - Finlandia 117
CA - Canada 90
AT - Austria 77
IN - India 76
FR - Francia 71
CI - Costa d'Avorio 65
JP - Giappone 60
TR - Turchia 58
NL - Olanda 45
PL - Polonia 45
KR - Corea 37
MX - Messico 37
SN - Senegal 34
AR - Argentina 28
UA - Ucraina 26
BD - Bangladesh 23
IR - Iran 22
PK - Pakistan 20
IQ - Iraq 17
ZA - Sudafrica 16
CZ - Repubblica Ceca 15
BE - Belgio 13
EC - Ecuador 13
ID - Indonesia 13
UZ - Uzbekistan 12
CH - Svizzera 11
MA - Marocco 11
SA - Arabia Saudita 11
VE - Venezuela 11
AU - Australia 10
PH - Filippine 10
ES - Italia 9
EG - Egitto 8
KE - Kenya 8
LT - Lituania 8
CO - Colombia 7
DZ - Algeria 7
IE - Irlanda 7
PT - Portogallo 7
PY - Paraguay 7
AE - Emirati Arabi Uniti 6
AZ - Azerbaigian 6
MY - Malesia 6
NG - Nigeria 6
JM - Giamaica 5
TW - Taiwan 5
DO - Repubblica Dominicana 4
HU - Ungheria 4
JO - Giordania 4
LB - Libano 4
PA - Panama 4
CL - Cile 3
DK - Danimarca 3
GH - Ghana 3
KG - Kirghizistan 3
KZ - Kazakistan 3
NO - Norvegia 3
PS - Palestinian Territory 3
RO - Romania 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
AL - Albania 2
AO - Angola 2
BJ - Benin 2
GD - Grenada 2
GT - Guatemala 2
MK - Macedonia 2
MO - Macao, regione amministrativa speciale della Cina 2
NI - Nicaragua 2
NP - Nepal 2
PE - Perù 2
QA - Qatar 2
TH - Thailandia 2
UG - Uganda 2
UY - Uruguay 2
BH - Bahrain 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
CU - Cuba 1
GE - Georgia 1
GQ - Guinea Equatoriale 1
HN - Honduras 1
IL - Israele 1
KI - Kiribati 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 11.913
Salva come PNG Salva come JPEG
Città #
Ashburn 745
Dallas 631
Hong Kong 524
Singapore 484
Fairfield 481
Santa Clara 401
Woodbridge 329
Chandler 272
Houston 232
Shanghai 207
Seattle 202
Wilmington 170
Milan 168
Beijing 167
Cambridge 167
New York 164
Sofia 160
Serra 156
Ann Arbor 139
Pisa 135
Boardman 133
Los Angeles 128
Munich 94
Florence 83
Princeton 78
Rome 66
Abidjan 65
Lawrence 59
Vienna 53
London 52
Hefei 51
Dong Ket 48
Turku 48
Medford 47
Bremen 46
Lucca 43
Lappeenranta 42
Ottawa 42
Des Moines 40
Redondo Beach 39
Tokyo 39
Chicago 36
Ho Chi Minh City 36
Frankfurt am Main 35
Dakar 34
Buffalo 32
Montignoso 31
Seoul 31
São Paulo 31
Istanbul 30
Warsaw 28
Ogden 27
Dearborn 25
Nanjing 24
Nuremberg 22
Redwood City 22
Bologna 21
Montreal 21
Naples 21
Livorno 20
Atlanta 19
Phoenix 18
Pistoia 18
Council Bluffs 15
Rio de Janeiro 15
Fuzhou 14
Toronto 14
Washington 14
Brooklyn 13
Guangzhou 13
Marseille 13
Poplar 13
San Diego 13
Chennai 12
Hanoi 12
Helsinki 12
Kent 12
Tashkent 12
Brno 11
Brussels 11
Padova 11
Shenzhen 11
Amsterdam 10
Izmir 10
Nanchang 10
Brasília 9
Curitiba 9
Porto Alegre 9
Turin 9
Wuhan 9
Belo Horizonte 8
Cascina 8
Changsha 8
Denver 8
Lancaster 8
Nairobi 8
Palermo 8
San Giuliano Terme 8
Aguascalientes 7
Boston 7
Totale 8.206
Salva come PNG Salva come JPEG
Nome #
COMPOSTI INIBITORI DELL’INFLAMMASOMA NLRP3 E LORO USO 246
Histochemical Detection of Collagen Fibers by Sirius Red/Fast Green Is More Sensitive than van Gieson or Sirius Red Alone in Normal and Inflamed Rat Colon 244
Protective Role of Flavonoids Against Colonic Motor Dysfunctions Associated with High Fat Diet-Induced Obesity 238
Protective effects of Saccharomyces boulardii CNCM I-745 Against Nonsteroidal anti-inflammatory drug-induced intestinal injury 209
A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation 205
Pathophysiology of NSAID-associated intestinal lesions in the rat: Luminal bacteria and mucosal inflammation as targets for prevention 203
Colonic dysmotility associated with high-fat diet-induced obesity: Role of enteric glia 193
Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors 191
Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients 191
Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic 186
NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same? 181
The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity 180
Prodromal Intestinal Events in Alzheimer's Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition 177
Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 176
Enteric protective effects of the combination Bifidobacterium longum and lactoferrin in a rat model of diclofenac-induced intestinal injury. 176
The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders 173
AMPK Activators as Novel Drug Candidates for the Treatment of Inflammatory Bowel Diseases 170
Preclinical development of fa5, a novel amp-activated protein kinase (Ampk) activator as an innovative drug for the management of bowel inflammation 167
Dietary Supplement, Containing the Dry Extract of Curcumin, Emblica and Cassia, Counteracts Intestinal Inflammation and Enteric Dysmotility Associated with Obesity 166
Dietary Supplementation with the Probiotic SF68 Reinforces Intestinal Epithelial Barrier in Obese Mice by Improving Butyrate Bioavailability 164
Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity 163
Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation 162
Mechanisms underlying the non-anticoagulant effects of apixaban and dabigatran on the integrity of intestinal mucosa: a comparative pre-clinical study. 159
Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications? 159
Involvement of the P2X7 purinergic receptor in colonic motor dysfunction associated with bowel inflammation in rats 158
Glial A2B Adenosine Receptors Modulate Abnormal Tachykininergic Responses and Prevent Enteric Inflammation Associated with High Fat Diet-Induced Obesity 156
The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications 155
Donepezil improves vascular function in a mouse model of Alzheimer's disease 155
Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models 154
Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System? 151
Protective effects of the combination Bifidobacterium longum plus lactoferrin against NSAID-induced enteropathy 149
NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodelling in a mouse model of diet-induced obesity 149
Enteric dysfunctions in experimental Parkinson's disease: alterations of excitatory cholinergic neurotransmission regulating colonic motility in rats 146
Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology 146
Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity 145
High Levels of β-Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse 145
Intestinal histomorphological and molecular alterations in patients with Parkinson's disease 143
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 142
USP7 and USP47 deubiquitinases regulate NLRP3 inflammasome activation 141
Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease 137
Anti-inflammatory effect of a novel locally acting A2A receptor agonist in a rat model of oxazolone-induced colitis. 137
Rifaximin Displays a Protective Activity in Experimental Enteropathy Induced by Indomethacin in Rats. 136
Adenosine signaling in the tumor microenvironment 135
Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases? 132
Use of Saccharomyces boulardii CNCM I-745 as therapeutic strategy for prevention of nonsteroidal anti-inflammatory drug-induced intestinal injury 131
The intestinal barrier in disorders of the central nervous system 130
Dietary flavonoids as a potential intervention to improve redox balance in obesity and related co-morbidities: a review 129
Deepening the Mechanisms of Visceral Pain Persistence: An Evaluation of the Gut-Spinal Cord Relationship 128
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis 127
Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy 124
P2X7 receptor-dependent tuning of gut epithelial responses to infection 123
Enteric Glia and Brain Astroglia: Complex Communication in Health and Disease along the Gut-Brain Axis 120
From the intestinal mucosal barrier to the enteric neuromuscular compartment: an integrated overview on the morphological changes in Parkinson's disease 118
Role of the A(2B) receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rat 117
Differential Impact of Weight Loss and Glycemic Control on Inflammasome Signaling 117
Opioid receptors beyond pain control: The role in cancer pathology and the debated importance of their pharmacological modulation 115
null 114
Role of cyclooxygenase pathways in bowel fibrotic remodelling in a murine model of experimental colitis 114
Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration 114
Role of proteinase-activated receptors 1 and 2 in nonsteroidal anti-inflammatory drug enteropathy 105
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 103
null 103
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology (npj Parkinson's Disease, (2022), 8, 1, (9), 10.1038/s41531-021-00263-x) 103
Intestinal epithelial barrier and neuromuscular compartment in health and disease 102
NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications 101
Neuronal regulation of intestinal immune functions in health and disease 100
Enteric glia at the crossroads between intestinal immune system and epithelial barrier: Implications for parkinson disease 99
Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases 98
Evaluation of the beneficial effects of a GABA-based product containing Melissa officinalis on post-inflammatory irritable bowel syndrome: a preclinical study 97
Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence 94
The pharmacological blockade of P2X4 receptor as a viable approach to manage visceral pain in a rat model of colitis 93
- Medicament for preventing or treating irritable bowel syndrome or inflammatory bowel diseases 93
Lactiplantibacillus plantarum HEAL9 attenuates cognitive impairment and progression of Alzheimer's disease and related bowel symptoms in SAMP8 mice by modulating microbiota-gut-inflammasome-brain axis 92
Ectopic Lymphoid Organs and Immune-Mediated Diseases: Molecular Basis for Pharmacological Approaches 92
Pharmacological modulation of P2X4 in inflammatory bowel diseases: the way towards novel therapeutics? 90
Glomerular hyperfiltration in morbid obesity: Role of the inflammasome signalling 89
The adenosine system at the crossroads of intestinal inflammation and neoplasia 87
Gut-directed therapy in Parkinson’s disease 84
Enteric glial NLRP3 inflammasome contributes to gut mucosal barrier alterations in a mouse model of diet-induced obesity 83
Inflammatory Bowel Diseases: It's Time for the Adenosine System 79
Development of an adipocyte differentiation protocol using 3T3-L1 cells for the investigation of the browning process: identification of the PPAR-γ agonist rosiglitazone as a browning reference drug 78
Prokineticin-2 Is Highly Expressed in Colonic Mucosa of Early Parkinson's Disease Patients 78
Pathological Remodeling of the Gut Barrier as a Prodromal Event of High-Fat Diet-Induced Obesity 77
NKG2A and COVID-19: another brick in the wall 77
LRRK2 is reduced in Parkinson’s disease gut 71
Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimer’s Disease 70
Editorial: IBD Management—Novel Targets and Therapeutic Perspectives 69
Adenosine signaling as target in cardiovascular pharmacology 67
Velusetrag rescues GI dysfunction, gut inflammation and dysbiosis in a mouse model of Parkinson's disease 62
α-Synuclein in Parkinson's Disease: From Bench to Bedside 60
The administration of Enterococcus faecium SF68 counteracts compositional shifts in the gut microbiota of diet-induced obese mice 59
Prolonged treatment with probiotics mitigates intestinal dysfunction and enteric Alzheimer's-related pathology in senescence-accelerated mice 59
LRRK2 expression in normal and pathologic human gut and in rodent enteric neural cell lines 56
Neuromuscular Function Abnormalities 54
Are LRRK2 mysteries lurking in the gut? 43
Gastrointestinal dysmotility in rodent models of Parkinson’s disease 41
Editorial: Reviews in neuropharmacology 2023: microbiota gut-brain axis, therapeutic insights for neurodegenerative diseases 34
Editorial: Neurological, Metabolic and Inflammatory Disorders: A Common Root in Inflammasome 29
How leaky is the gut in Parkinson’s disease? 21
Small Intestine Neuromuscular Dysfunctions and Neurogliopathy in a Mouse Model of High-Fat Diet-Induced Obesity: Involvement of Toll-Like Receptor 4 2
Totale 12.306
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.799
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.799
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021501 0 0 0 0 0 33 31 53 102 119 39 124
2021/2022751 27 16 18 25 146 113 41 36 62 41 49 177
2022/20231.195 120 151 89 93 114 138 24 106 220 41 78 21
2023/20241.326 78 105 162 98 184 218 49 80 79 49 111 113
2024/20253.443 56 114 72 192 266 413 328 142 382 403 371 704
2025/20262.622 296 480 705 436 472 233 0 0 0 0 0 0
Totale 12.306